Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
Key takeaways
- Vaccine stocks are reacting to a Russian plague scare and company‑specific moves, with Moderna and Vaxcyte seeing modest gains and Novavax sliding slightly.
- Moderna after‑hours price: $203.56
- Moderna regular session gain: 6.95% to $203.21
- Vaxcyte after‑hours price: $70.60
What happened
Shares of Moderna (MRNA), Vaxcyte, and Novavax moved after hours on Monday following a suspected pneumonic plague case in Russia. Moderna gained 0.17% to $203.56 after the bell, having risen 6.95% during the regular session to $203.21. Novavax fell 0.88% to $12.45, and Vaxcyte dropped 4.36% to $70.60 after a 20.08% gain in the regular session. Vaxcyte also announced a $1 billion capital raise—$500 million in common stock and pre‑funded warrants plus $500 million in convertible senior notes due…
Why it matters
The Russian outbreak has kept vaccine makers in the spotlight, potentially boosting demand for pneumococcal and other vaccines. Moderna’s modest after‑hours rise follows its COO appointment and upcoming launch of intismeran autogene with Merck, signaling continued pipeline momentum. Vaxcyte’s capital raise could…
Short-term and longer-term
Short-term. In the next 24–48 hours, watch for price swings around the $203 level for MRNA as the market digests the COO appointment and intismeran launch plans.
Longer-term. Over the coming months, MRNA’s partnership with Merck and VAX‑31’s development trajectory could influence long‑term valuation multiples.